person
Paula R. O.
- Country
- Spain
- Department
- Hematología
Research Overview
assignment
4
Clinical Trials ·
- Dose-Escalation Study of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma
- Long-term Follow-up Study on Delayed Adverse Events and Safety Profile of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma
- Phase III Trial Comparing Extended Lenalidomide-Bortezomib-Dexamethasone with Early Rescue vs. Isatuximab-Lenalidomide-Bortezomib-Dexamethasone vs. Isatuximab-Lenalidomide-Iberdomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Candidates for Autologous Stem Cell Transplantation
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
7
Sites with multiple studies
Has run more than one trial at 7 of 65 partner sites.
Specializations
Multiple Myeloma Treatment Innovation
The investigator specializes in evaluating novel therapeutic approaches for multiple myeloma, with particular emphasis on bispecific antibodies and CAR-T cell therapies.
- Novel Immunotherapies
- Treatment Combinations
- Targeted Therapies
Disease Stage Focus
Conducts research across various stages of multiple myeloma, including newly diagnosed cases, relapsed/refractory disease, and high-risk smoldering multiple myeloma.
- Treatment-Resistant Disease
- Early Disease Intervention
- Disease Progression Management
Therapeutic Development
Investigates emerging treatments including monoclonal antibodies, cell-based therapies, and combination therapeutic approaches.
- Advanced Treatment Modalities
- Drug Resistance Solutions
- Treatment Optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.